Drug Trial Radar · NCT06991556
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
168
Actual
Start
Jul 7, 2025
Primary completion
Dec 3, 2026
Study completion Oct 18, 2035
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase II study aims to evaluate efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg once a day (QD) doses + abiraterone compared with an androgen receptor pathway inhibitor (ARPI, abiraterone or enzalutamide) in participants with metastatic Hormone Sensitive Prostate Cancer (mHSPC) and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and PK data from participants randomized in the study will be evaluated
Conditions
- Metastatic Hormone-sensitive Prostate Cancer
Interventions
JSB462Drug
JSB462 is administered orally, daily and continuously (100 mg or 300 mg QD) until disease progression per PCWG3-modified RECIST 1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision.
AbirateroneDrug
Abiraterone 1000 mg is administered orally, daily and continuously until disease progression per PCWG3-modified RECIST 1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision.
EnzalutamideDrug
Enzalutamide 160 mg is administered orally, daily and continuously until disease progression per PCWG3-modified RECIST 1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Prostate Specific Antigen 90 (PSA90) RateTime frame: From date of randomization till 30 days safety fup, assessed up to approximately 75 months
- Incidence rate of adverse events (AEs)Time frame: From date of randomization till 30 days safety fup, assessed up to approximately 75 months
- Number of participants with dose adjustmentsTime frame: From date of randomization till 30 days safety fup, assessed up to approximately 75 months
- Duration of exposure to study treatmentTime frame: From date of randomization till 30 days safety fup, assessed up to approximately 75 months
Locations
64 sites in 15 countries. Site status is shown where the registry gives one.
University of California San Diego - Moores Cancer Center
La Jolla, California
Saint Johns Cancer Institute
Santa Monica, California
Rocky Mountain Cancer Centers
Denver, Colorado
Yale Cancer Center
New Haven, Connecticut
Advanced Urology Ins Daytona Beach
Daytona Beach, Florida
Emory University School of Medicine-Winship Cancer Institute
Atlanta, Georgia
Associated Urological Specialists
Chicago Ridge, Illinois
Mass General Hospital
Boston, Massachusetts
Michigan Institute of Urology
West Bloomfield, Michigan
XCancer Omaha LLC
Omaha, Nebraska
Perlmutter Cancer Centre
New York, New York
Associated Med Professionals of NY
Syracuse, New York
Montefiore Medical Center
The Bronx, New York
MidLantic Urology
Bala-Cynwyd, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Carolina Urologic Research Center
Myrtle Beach, South Carolina
Tennessee Oncology
Nashville, Tennessee
Urology San Antonio
San Antonio, Texas
Inova Schar Cancer Institute
Fairfax, Virginia
Virginia Oncology Associates
Norfolk, Virginia
Fred Hutch Cancer Research
Seattle, Washington
Novartis Investigative Site
Adelaide, South Australia, Australia
Novartis Investigative Site
Clayton, Victoria, Australia
Novartis Investigative Site
Fortaleza, Ceará, Brazil
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Vancouver, British Columbia, Canada
Novartis Investigative Site
Halifax, Nova Scotia, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Beijing, Chaoyang, China
Novartis Investigative Site
Brno, Czechia
Novartis Investigative Site
Olomouc, Czechia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Quint-Fonsegrives, France
Novartis Investigative Site
Suresnes, France
Novartis Investigative Site
Nice, Alpes Maritimes, France
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Lübeck, Germany
Showing 40 of 64 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.